Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-21. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Expansion of high-margin growth drug revenues to 60% of product mix offsets patent cliff expiry risk and compresses BMY's forward P/E valuation discount against XLV peers.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factBristol Myers Squibb generated $12.9 billion in Q2 revenue with 153% year-over-year EPS growth. |
| What else was confirmed? | Reported factBMY's portfolio of newer growth drugs expanded 15% year-over-year, reaching nearly 60% of total company revenue. |
| Does the valuation support acting? | Interpretation1 stored valuation assumptions for BMY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownBMY Growth Portfolio Revenue Share — Monitor whether growth portfolio surpasses 60% total revenue in Q3 release. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Bristol Myers Squibb generated $12.9 billion in Q2 revenue with 153% year-over-year EPS growth.
- · BMY's portfolio of newer growth drugs expanded 15% year-over-year, reaching nearly 60% of total company revenue.
- · BMY shares have appreciated 17% year-to-date while continuing to trade at a valuation discount relative to biopharma peers.
Public research record
Research framework · page evidenceCompleted event assessment
forward earnings multiple rerating on product mix shift
| Type | Claim | Scope |
|---|---|---|
| Assumption | Bristol Myers Squibb generated $12.9 billion in Q2 revenue with 153% year-over-year EPS growth. | 2026-09-21 |
| Interpretation | forward earnings multiple rerating on product mix shift | BMY |
Countercase, invalidators, and sources
Continued double-digit growth in new drug franchises closes the valuation multiple discount versus peer group averages.
- · BMY Growth Portfolio Revenue Share — Monitor whether growth portfolio surpasses 60% total revenue in Q3 release.
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder · 2026-09-20
What remains unresolved
- Base path
- BMY maintains defensive outperformance within large-cap healthcare supported by 15% growth in core commercial lines.
- Adverse path
- Accelerating generic erosion in legacy compounds outpaces new product uptake, stalling margin expansion.
- Supportive path
- Continued double-digit growth in new drug franchises closes the valuation multiple discount versus peer group averages.
- · BMY Growth Portfolio Revenue Share — Monitor whether growth portfolio surpasses 60% total revenue in Q3 release.next month
Evidence
- Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder2026-09-20
“Bristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue...”
Supports: BMY posted $12.9B in Q2 revenue with 153% EPS growth and 60% revenue from growth portfolio.